The major aldosterone metabolite 3␣,5␤ tetrahydroaldosterone reflects up to 45% of the aldosterone secretion. Its 24-h urinary excretion is likely to provide an accurate index of the daily aldosterone production and to be an indicator for primary aldosteronism (PA).
C urrent evidence suggests that primary aldosteronism (PA) is not a rare cause of hypertension. It may account for 10% to 12% of hypertensive cases, not only in hypertension units, 1 but also in a general practice. 2 Nevertheless, PA is often overlooked. 1, 3 Screening for PA can be difficult, as some of the biochemical features of the syndrome (hypokalemia, suppressed plasma renin activity, and high plasma aldosterone concentration) may be absent. 4, 5 Recently, an elevated ratio of plasma aldosterone to plasma renin activity was proposed as a better screening tool. 3, 6, 7 However, a considerable overlap of the results between patients with PA and those with low-renin essential hypertension (EH) may be expected, as a high ratio can be due to a low plasma renin activity despite normal plasma aldosterone. Hence, an elevated aldosterone should be the main part of the screening approach.
Measurements of aldosterone in 24-h urine samples, which may reflect the aldosterone secretion more accurately than "spot" plasma aldosterone estimations and may be more appropriate for PA screening. The methods used are the estimation of free (unconjugated) aldosterone, which represents 0.5% of the aldosterone secreted daily, or the estimation of one of the metabolites of aldosterone; aldosterone-18-glucuronide or 3␣,5␤ tetrahydroaldosterone. 8 -10 Aldosterone-18-glucuronide (usually termed al-dosterone excretion rate), is mostly formed in the kidneys and accounts for 5% to 10% of the 24-h aldosterone secretion. However, normal values of this metabolite were found in a considerable percentage of PA patients. 4,9 -11 Tetrahydroaldosterone is formed in the liver and represents 30% to 45% of the aldosterone secretion. It may therefore be more accurate in reflecting the daily aldosterone production than free aldosterone and aldosterone-18-glucuronide.
A prospective study was conducted with the following objectives: 1) to investigate the sensitivity and specificity of 24-h urinary tetrahydroaldosterone as compared with free aldosterone and aldosterone-18-glucuronide, as well as with plasma aldosterone, plasma renin, and the plasma aldosterone/plasma renin activity ratio in normal subjects and in a large population with hypertension to define a reliable screening test for PA; and 2) to evaluate the prevalence of falsely high serum potassium values in PA patients due to the techniques used for blood sampling.
Subjects and Methods

Population Studies
Control subjects (n ϭ 111) participating in the study were normotensive healthy volunteers recruited from the staff of the hospital. From the hypertensive patients consecutively referred by their primary care physicians or by other hospitals for comprehensive evaluation at our center, 1865 patients in whom other secondary forms of hypertension had been ruled out were subjected to a protocol designed to identify PA. The protocols were approved by the ethics commission of the hospital, and informed consent of all participants was recorded and witnessed. Antihypertensive medications were withdrawn for at least 2 weeks and spironolactone for 6 weeks before commencement of the study. In patients in whom medication could not be discontinued, prazosin or clonidine 12 was substituted until examination, at a dosage sufficient to achieve an acceptable reduction of blood pressure.
Screening Protocol
Serum Potassium In all participants, blood samples were obtained for potassium determinations at the central laboratory of the hospital. Furthermore, the effect of blood sampling technique was evaluated in 21 EH patients and in 152 patients with confirmed PA. Blood was drawn twice at the hypertension unit for potassium determinations; first, with a tourniquet and repeated fist-clenching, and second without using a tourniquet and without repeated fistclenching 13 while blood was obtained without aspiration. The blood samples were centrifuged at 2000 g for 15 min, and the serum was immediately separated for potassium estimations. The potassium values obtained with the two methods (with and without fist clenching) were compared.
Plasma Aldosterone and Plasma Renin Activity Blood samples were obtained in all subjects and patients after recumbency for 1h between 8:00 and 10:00 AM. Thereafter, the plasma aldosterone to renin activity ratio (PARR) was calculated by dividing the plasma aldosterone (PALD) value (ng/dL) by the simultaneous plasma renin activity (PRA) (ng angiotensin I/mL/h).
Urinary Steroids Subjects and patients collected 24-h urine samples, which were kept refrigerated until analysis. In all samples, tetrahydroaldosterone, aldosterone-18-glucuronide, and free aldosterone were determined in addition to sodium, potassium and creatinine. All participants were on their usual noncontrolled sodium diet.
Verification of PA Diagnosis
To confirm PA and to differentiate between adrenal adenoma and hyperplasia as the cause for PA, the following tests were done: The effect of posture on PALD and PRA was studied in all normotensives and hypertensive patients. In all patients with borderline or elevated aldosterone values on screening or with unusual posture test results, an intravenous saline load test (2 L 0.9% NaCl from 8:00 to 12:00 AM) and a high-resolution computed tomography (CT) of the adrenals were performed. In addition to CT, dexamethasone-suppressed scintigraphy (n ϭ 141) or adrenal venous sampling (n ϭ 179) were undertaken in established PA cases. The circumstance that adrenal vein sampling could not be performed in more than the 179 cases might have resulted in underestimation of the proportion of adrenal adenoma by the CT.
14 Nevertheless, the dexamethasone-suppressed scintigraphy corroborated the CT diagnosis in 127 of the 141 patients in whom it was performed.
In some patients with proven PA, normal excretions of aldosterone-18-glucuronide but high tetrahydroaldosterone values were found. In 20 such patients, aldosterone secretion rates were determined to prove an excessive aldosterone production. For this purpose, the urinary steroids were determined after intravenous injection of 3 Hlabeled aldosterone as described by Vecsei et al and by Glaz and Vecsei.
15,16
Analytical Methods
Urinary tetrahydroaldosterone, aldosterone-18-glucuronide and free aldosterone were determined by radioimmunoassay (RIA) after extraction and chromatographic purification as reported previously. 8, 17, 18 Tetrahydroaldosterone was measured after treatment with glucuronidase from Helix pomatia digestive juice. Aldosterone-18-glucuronide was measured after 24-h acid hydrolysis (pH1). PALD and PRA were determined by RIA. 17, 19, 20 
Statistical Analysis
Differences of the values between the groups examined were evaluated by the Wilcoxon test, with P values Ͻ .05 being considered significant. The diagnostic value of serum potas-sium, PALD, PRA, PARR, tetrahydroaldosterone, aldosterone-18-glucuronide, and free aldosterone in differentiating PA from EH patients was first investigated with logistic regression analysis. Thereafter, the sensitivities and specificities to differentiate between PA and EH were determined. Several cut-off points of the values obtained with each test were calculated using receiver operator characteristic (ROC) curve analyses. The optimal cut-off point leading simultaneously to high sensitivity and specificity was chosen.
Results
Clinical Characteristics
Of the 1865 patients examined, 412 cases were classified as PA and 1453 patients as EH. The diagnosis of PA was based on elevated aldosterone values, suppressed PRA (in the majority of cases, vide infra) and on the results of the diagnostic tests mentioned above. Accordingly, an aldosterone-producing adenoma could be diagnosed in 227 of the 412 patients and was confirmed by surgery and pathological examination. An idiopathic hyperaldosteronism resulting from adrenal hyperplasia was assumed in 185 cases. Diagnosis of EH was considered when PA could be conclusively ruled out. According to the PRA values, EH patients were divided into low-, normal-, and high-renin EHs. Low-renin EH was defined as a PRA of Ͻ0.45 ng angiotensin I/mL/h in the upright position. Demographic and analytical data of all participants are shown in Table 1 .
Results of Screening Approach
Serum Potassium Fasting potassium values obtained at the routine laboratory of the hospital were lower in PA than in EH patients (Table 1) . However, 70.4% of patients with PA had potassium values Ͼ3.6 mmol/L. As shown in Table  2 , fist-clenching while blood sampling caused a considerable rise in potassium concentration in the EH and PA patients examined. Under this maneuver, values Ͼ3.6 mmol/L were obtained in 69.1% of the PA cases, similar to the values obtained at the laboratory of the clinic. By avoiding the maneuver, potassium values greater than 3.6 mmol/L were found only in 10.5% of PA patients (Table 2) .
Plasma Renin Activity The median of supine PRA values in patients with PA was significantly lower than in EH and control subjects (Table 1) . Of the PA patients, 93.5% had low supine PRA values (Ͻ0.9 ng angiotensin I/mL/h, which is the median achieved in control subjects). Twenty PA patients (5.0%) had normal (0.9 to 2.0 ng angiotensin I/mL/h) and six (1.5%) had high (Ͼ2.0 ng angiotensin I/mL/h) values. Of the PA patients with normal or high PRA, six had elevated serum creatinine values above 1.2 mg/dL. Of the EH patients, 54% had also PRA values Ͻ0.9 ng angiotensin I/mL/h. Plasma Aldosterone/Renin Activity Ratio In general, PA patients show higher ratios than the EH patients ( Table  1 ). The median of the values obtained in the low-renin EH group was 50. Using this as the standard for comparison, 33% of the PA patients exhibited ratios lower than 50. On the other hand, 49.3% of the low-renin EH group showed ratios Ͼ50, similar to those in the PA patients. Of the 91 PA patients with normal PALD on screening, 54 had a ratio of Ն25. This ratio was considered suspicious for PA.
Plasma Aldosterone
Patients with EH and high PARR were intensively evaluated, including CT of the adrenals in 42 patients, but PA diagnosis could be ruled out. Tetrahydroaldosterone values are depicted in Table 3 . PA patients had high values that could distinguish 95% of PA patients from EH patients. Of the PA cases, 5% showed normal tetrahydroaldosterone values. However, their free aldosterone and aldosterone-18-glucuronide were elevated.
Urinary (24-h) Aldosterone Values
Aldosterone-18-Glucuronide was within the normal range in 45.6% of PA patients, whereas tetrahydroaldosterone and free aldosterone excretions were elevated (Table 3) . Aldosterone secretion rate was examined in 20 such patients and was found to be elevated (median 763.0 g/24 h (range 364.0 to 1986.0), normal range 50 to 150 g/24 h), indicating an elevated aldosterone production, but altered excretion of the aldosterone-18-glucuronide fraction. When we compared PA patients with high aldosterone-18-glucuronide excretions with patients with normal aldosterone-18-glucuronide excretions, the first group showed significantly higher PALD, tetrahydroaldosterone, and free aldosterone values than those found in the second group. Hence, the aldosterone production in the first group must be higher than in the second.
Free Aldosterone Patients with PA excreted significantly larger amounts than those with EH (Table 3) . However, free aldosterone was within the normal range in 24.8% of PA cases, while tetrahydroaldosterone and aldosterone-18-glucuronide were elevated. However, these values do not differentiate between the patient groups.
Adrenal Adenoma Versus Hyperplasia
Sensitivity and Specificity of Screening Tests Applied
Using forward selection, univariate as well as multivariate logistic regression analyses for the tests applied in the study showed very similar results. The results of the sensitivity and specificity of the tests at an optimal cut-off calculated by ROC curve analyses are presented in Table 4 and Fig. 1 . Tetrahydroaldosterone proved to be the best test to detect PA, followed by PALD, free aldosterone, PARR, and aldosterone-18-glucuronide. We also investigated the diagnostic value of combined use of PALD and PARR in differentiating PA from EH cases. A PARR of Ն25 combined with a PALD value of Ն9 ng/dL provided a lower sensitivity but a higher specificity than PARR alone. However, the sensitivity of the two parameters was lower than that of PALD and that of tetrahydroaldosterone.
Discussion
In this prospective study on the search for a practicable but valid screening method for PA, an attempt was made to reassess the diagnostic relevance of serum potassium, PRA, PALD, and PARR, and to examine the validity of urinary tetrahydroaldosterone, aldosterone-18-glucuronide, and free aldosterone in this respect. Potassium proved to be an unsatisfactory screening parameter. Absence of hypokalemia in PA had previously been well documented in up to 30% of the patients, 4,5 but recent studies indicate even higher prevalences of normokalemic PA 1, 3, 21 , suggesting that the test may be invalid. 22 In this study, serum potassium estimated under "routine laboratory conditions" was within the normal range in 70.4% of PA cases. It is well established that the common practice of forearm exercise, in a limb in which the circulation is restricted (as an aid to venipuncture) could be a potent cause of erroneously high potassium readings (due to local release of potassium from the muscles) in normal subjects and patients, to a level sufficient to obscure the suspicion of hyperaldosteronism. 13, 23 Avoiding this maneuver, we found normal potassium values in only 10.5% of PA cases examined. As this possibility cannot be ruled out in daily routine work, and as normokalemic PA does exist, exclusive reliance on potassium estimates in preselecting patients with regard to PA should be avoided. 5 Nevertheless, unprovoked hypokalemia should still be considered as a relevant parameter in this respect.
In this study, renin as screening test proved to have a low sensitivity and a modest specificity. Moreover, a normal or elevated PRA does not necessarily rule out PA, as has been shown by other investigators. 5 Because renin can be modified by antihypertensive agents 24 and pretreatment status may be difficult to reattain after treatment, some PA patients may present with normal or even high PRA values. 5 It had also been reported 25 that in patients with severe hypertension due to PA, PRA can escape suppression if hypertensive kidney damage occurs. Therefore, the screening value of PRA is also limited especially in PA patients with severe hypertension, who still profit from adrenalectomy or cautious spironolactone treatment. 25, 26 Furthermore, plasma aldosterone was normal in 22% of patients with PA in the present study, resulting in low sensitivity. This can be due to episodic and circadian variations in aldosterone secretion, 27 making a single plasma aldosterone determination of little practical use. Therefore, several investigators anticipated that a high ratio of plasma aldosterone to PRA (PARR) would be more appropriate in distinguishing PA from EH. 3, 6, 7 We found a considerable overlap of the PARR values between PA and EH, especially in low-renin EH, resulting in low sensitivity and specificity. Besides this, the ratio was not consistently elevated in PA patients. Different cut-off points of the ratio have been reported 3, 4 as thresholds for further investigation for suspected PA. In the present study, a ratio of 25 was calculated, which had a sensitivity and specificity that enabled us to recognize 54 of 91 confirmed PA cases exhibiting normal PA on screening. However, tetrahydroaldosterone was elevated in all of these cases. Using a ratio of Ͼ25, Fardella et al 21 could also diagnose 13 cases (showing normal PALD on screen- ing) of 29 cases as PA. However, urinary steroids were not examined in their study. Furthermore, we found that the combined use of both PALD and PARR showed a higher specificity but a lower sensitivity than PARR alone. In consequence of the low sensitivity of these parameters, a substantial number of PA cases would escape diagnosis. Hence, caution is called for in using the PARR. 22 In any case, an elevated aldosterone level should be an indispensable screening criterion. 7 In this study, urinary tetrahydroaldosterone showed the highest sensitivity and specificity in distinguishing PA from EH patients. However, 5% of PA patients showed normal tetrahydroaldosterone values; this may result from a low hepatic transformation of aldosterone. 28 These patients, however, had negative histories of liver disease and had normal functional laboratory test results. Griffing et al 29 found that medication with hydrochlorothiazide over a period of 28 days lowered the fractional excretion of tetrahydroaldosterone. Our patients were off medication for at least 2 weeks, which was probably not long enough to rule out a treatment-related fractional reduction of tetrahydroaldosterone. Because the patients had been on at least two antihypertensive medications, further studies are needed to elucidate the effect of treatment on tetrahydroaldosterone excretion rates.
In respect of urinary aldosterone-18-glucuronide, we found normal values in a large number of PA cases, whereas tetrahydroaldosterone was elevated. Normal aldosterone-18-glucuronide excretions in PA were previously reported in studies on a small number of cases. 4, 9, 11, 20 It can be assumed that PA cases with normal aldosterone-18-glucuronide could have had undetectable kidney lesions. This is a possibility that we have not yet intensively studied. Alternatively, these cases may represent a moderate overproduction of aldosterone with relatively lower renal aldosterone metabolism, whereas liver metabolism resulting in high tetrahydroaldosterone values predominates. In these cases, aldosterone-18-glucuronide would not have been an adequate screening parameter. It is also of much lower sensitivity than tetrahydroaldosterone, as we found in this study. Free aldosterone proved to have a higher sensitivity than aldosterone-18-glucuronide, but its sensitivity was lower than that of tetrahydroaldosterone.
The data obtained suggests that patients suspected of having PA should have tetrahydroaldosterone determination as an initial test. However, our data also indicate that a single test is not sufficient. Because tetrahydroaldosterone can be normal in a few cases, the simultaneous estimation of the three urinary aldosterone parameters in the same urine sample makes the diagnosis of PA highly probable. This proposed method of screening is justified since early detection and possible surgery for adrenal adenoma would obviate a costly lifelong antihypertensive PARR ϭ plasma aldosterone/renin activity ratio. Sensitivity ϭ percentage of patients with primary aldosteronism (true positive cases). Specificity ϭ percentage of cases without primary aldosteronism that are classified as essential hypertensive patients. * ng angiotensin I/mL/h.
FIG. 1.
Result of receiver operator characteristic (ROC) curve analysis for sensitivity and specificity of the investigated variables in differentiating primary aldosteronism patients from essential hypertensive cases. P-ALDOS ϭ plasma aldosterone; RPLADRE ϭ plasma aldosterone/plasma renin activity ratio; UA18 OH ϭ 24-h urinary aldosterone-18-glucuronide; U-FALD ϭ 24-h urinary free aldosterone; U-TH-A ϭ 24-h urinary tetrahydroaldosterone.
therapy. Otherwise, administration of spironolactone would be preferable to using other antihypertensives. The 24-h urine sampling method has proved to be a practical and convenient tool for screening that can be performed on an outpatient basis and can be applied by family doctors who have to decide whether or not to refer a patient for further investigations. In view of the reasons for referral of cases to our unit, patients should be screened for PA on poor response to treatment with two antihypertensive drugs, whenever spontaneous hypokalemia or an adrenal adenoma is detected incidentally. The conventional method of tetrahydroaldosterone determination required hydrolysis of the conjugate, extraction, and chromatographic separation.
9,30,31 before radioimmunoassay. However, an assay with a single purification step has been published. 18 Furthermore, a direct radioimmunoassay for tetrahydroaldosterone glucuronide in unprocessed urine had been reported 32 ; if the reagents are available, this would simplify screening. Moreover, a mass spectrometric determination method has been established 33 and has proved to be clinically applicable. Hence, wider use of tetrahydroaldosterone determination is feasible.
